Medical cannabis products are legal in the UK from today – in very limited circumstances. This could include products without marketing authorisation, if approved by a registered specialist in certain conditions.
A change in the law brought about in a few short months enables cannabis-based products for medicinal use in humans to be prescribed as a Schedule 2 drug – essentially drugs that can be legally prescribed but carry higher risks for potential abuse.
This could be a special medicinal product for use at the direction of a doctor on the General Medical Council’s specialist register; an investigational medicinal product without marketing authorisation for use in a clinical trial; or a medicinal product with a marketing authorisation.
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.